contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


lipidor-announces-database-lock-in-its-phase-iii-clinical-study-of-the-psoriasis-candidate-akp02g2

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Lipidor

STOCKHOLM, Sweden, 19th May 2025 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the company's Phase III study of AKP02G2 for the treatment of psoriasis has...

<div class="mfn-preamble"><p><strong>STOCKHOLM, Sweden, 19</strong><strong><sup>th</sup></strong><strong> May 2025 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the company's Phase III study of AKP02G2 for the treatment of psoriasis has reached “Database Lock” in its clinical development program. The next step is statistical analyses of the data to compile the results. Lipidor will publish the primary results during the last week of May, according to the previously communicated timeline.</strong></p></div><div class="mfn-body"><p>The primary goal of the study is to demonstrate good therapeutic effect for the treatment of mild to moderate psoriasis on both the body and the scalp. The psoriasis candidate AKP02G2 combines calcipotriol and betamethasone dipropionate and is based on Lipidor’s patented AKVANO® technology. Lipidor has chosen to compare the sprayable drug candidate AKP02G2 with Enstilar, which is a market-leading preparation for topical treatment for psoriasis. AKP02G2 contains the same combination of active substances as Enstilar. After the database closing, unblinding will carried out so that Cliantha statisticians can conduct analysis of the study's results.</p><p>“We are pleased to announce that our Phase III study with the psoriasis candidate AKP02G2 has reached database lock and we look forward to presenting the primary results from the study before the end of May," says Ola Holmlund, CEO, Lipidor AB.</p><p><strong>Publication</strong></p><p>The information was provided by&nbsp;Lipidor’s&nbsp;CEO for publication on&nbsp;19<sup>th</sup> May at 8.30am (CEST).</p></div><div class="mfn-footer mfn-contacts mfn-ec2f69be0eda"><p><strong class="mfn-heading-1">For more information, please contact:</strong></p><p>Ola Holmlund, CEO, Lipidor AB (publ)<br>Telephone: +46 (0) 72 50 70 369<br>Email: <a rel="noopener" href="mailto:ola.holmlund@lipidor.se">ola.holmlund@lipidor.se</a></p><p>The company’s Certified Adviser is DNB Carnegie Investment Bank AB.</p></div><div class="mfn-footer mfn-about mfn-e061b566de55"><p><strong class="mfn-heading-1">About Lipidor AB</strong><br>Lipidor AB (Nasdaq First North Growth Market: LIPI) (<a rel="noopener" href="http://www.lipidor.se">www.lipidor.se</a>) is a pharmaceutical development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The company can develop topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of&nbsp;proven&nbsp;pharmaceutical substances. Lipidor’s priority project is AKP02G2, which focusses on psoriasis.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/d601c670-9cd8-4bb6-80bf-d33a39b7c766/lipidor-announces-database-lock-in-its-phase-iii-clinical-study-of-the-psoriasis-candidate-akp02g2.pdf" class="mfn-generated mfn-primary">Lipidor announces database lock in its Phase III clinical study of the psoriasis candidate AKP02G2</a></p></div>

Lipidor announces database lock in its Phase III clinical study of the psoriasis candidate AKP02G2